

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

### Single Technology Appraisal (STA)

#### Febuxostat for the treatment of hyperuricaemia in patients with gout

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Ipsen Limited (febuxostat)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Age Concern England</li> <li>• Arthritis and Musculoskeletal Alliance (ARMA)</li> <li>• Arthritis Care</li> <li>• Arthritis Research Campaign</li> <li>• British Kidney Patient Association</li> <li>• British Nutrition Foundation</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Help the Aged</li> <li>• Kidney Alliance</li> <li>• Kidney Research UK</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• National Kidney Federation</li> <li>• National Rheumatoid Arthritis Society</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• UK Gout Society</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Renal Industries</li> <li>• Association of Renal Technologists</li> <li>• British Association for Services to the Elderly</li> <li>• British Dietetic Association</li> <li>• British Geriatrics Society</li> <li>• British Health Professionals in</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>• National Public Health Service for Wales</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Kidney Patients Association</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Amdipharm (sulfipyrazone)</li> <li>• GlaxoSmithKline (allopurinol)</li> <li>• Merck Sharp and Dohme (probenecid)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• School of Health &amp; Related Research Sheffield</li> <li>• National Coordinating Centre for Health Technology Assessment</li> </ul>

National Institute for Health and Clinical Excellence

Matrix of consultees and commentators for the appraisal of febuxostat for the treatment of hyperuricaemia in patients with gout

Consultees	Commentators (no right to submit or appeal)
<p>Rheumatology</p> <ul style="list-style-type: none"> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Orthopaedic Association</li> <li>• British Pain Society</li> <li>• British Renal Society</li> <li>• British Society for Rheumatology</li> <li>• Chartered Society of Physiotherapy</li> <li>• College of Occupational Therapists</li> <li>• Physiotherapy Pain Association</li> <li>• Primary Care Rheumatology Society</li> <li>• Renal Association</li> <li>• Rheumatoid Arthritis Surgical Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal Society of Medicine - Forum on Intellectual Disabilities</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Society for DGH Nephrologists</li> <li>• Society for Endocrinology</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Bassetlaw PCT</li> <li>• Department of Health</li> <li>• Sunderland Teaching PCT</li> <li>• Welsh Assembly Government</li> </ul>	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

## Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the appraisal.

<b>Consultees</b>	
<b>Manufacturer</b>	<b>Generic Name</b>
Ipsen Limited	Febuxostat
<b>Commentators</b>	
<b>Manufacturer</b>	<b>Generic Name</b>
Amdipharm	sulfinpyrazone
GlaxoSmithKline	allopurinol
Merck Sharp and Dohme	probenecid
Novartis Pharmaceuticals UK Ltd	sulfinpyrazone
Roche Products Ltd	allopurinol

National Institute for Health and Clinical Excellence

Matrix of consultees and commentators for the appraisal of febuxostat for the treatment of hyperuricaemia in patients with gout

Issue date: August 2007

Page 4 of 4